Table 3.
Analyses of the participants progressing to severe COVID-19 with subgroups based upon different at-risk definitions.
| Placebo | NTZ | OR (95% CI) | P-value | Relative Reduction | |
|---|---|---|---|---|---|
| All SARS-CoV-2-Positive Participants | 7/195 (3·6%) | 1/184 (0·5%) | 5·6 (0·7–46·1) | 0·07 | 85% |
| Subgroups: | |||||
| “May Be” or “At Increased Risk” for Severe COVID-19 Illness per CDC (protocol-defined stratification factor) | 7/126 (5·6%) | 1/112 (0·9%) | 6·5 (0·8–53·4) | 0·05 | 84% |
| At Increased Risk for Severe COVID-19 Illness per CDC | 7/121 (5·8%) | 1/104 (1·0%) | 6·3 (0·8–52·3) | 0·05 | 83% |
| At High Risk of Progressing to Severe COVID-19 and/or Hospitalization (per EUA documents for monoclonal antibodies)1 | 6/69 (8·7%) | 1/60 (1·7%) | 5·6 (0·7–48·1) | 0·08 | 81% |
1
≥ 65 years of age, BMI ≥35 kg/m2, chronic kidney disease, diabetes, immunosuppressive disease, current receipt of immunosuppressive treatment, or ≥55 years of age with at least one of cardiovascular disease, hypertension, or chronic obstructive pulmonary disease or another chronic respiratory disease.